Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Corporate Profile

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor that we are evaluating in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities to overcome treatment resistance and deliver superior clinical benefit compared the SoC.

Company Overview (button) - September 2023
Recent News
Sep 26, 2023

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% (vs. 7.7%) and...

Sep 5, 2023

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of...

Aug 9, 2023

- New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 - - Advance to first-line mCRC follows...

More >

Stock Information
NASDAQCRDF
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@cardiffoncology.com

Contact

Events
September 26, 2023
5:00pm EDT
August 7, 2023
5:00pm EDT